impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Calcineurin inhibitors for adult-onset Still’s disease: a multicentre retrospective cohort study

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13

 

  1. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo,and Department of Internal Medicine, Tomakomai City Hospital, Tomakomai, Japan.
  2. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. edaichi@med.hokudai.ac.jp
  3. Department of Internal Medicine, Tomakomai City Hospital, Tomakomai, and Department of Internal Medicine, Kushiro Red Cross Hospital, Kushiro, Japan.
  4. Department of Internal Medicine, Kushiro Red Cross Hospital, Kushiro, Japan.
  5. 3rd Department of Internal Medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan.
  6. Department of Internal Medicine, Takikawa Municipal Hospital, Takikawa, Japan.
  7. Department of Internal Medicine, Japanese Red Cross Kitami Hospital, Kitami, and Department of Rheumatology, Tonan Hospital, Sapporo, Japan.
  8. Department of Internal Medicine, Japanese Red Cross Kitami Hospital, Kitami, Japan.
  9. Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital, Sapporo, Japan.
  10. Department of Rheumatology, NTT-East Sapporo Hospital, Sapporo, Japan.
  11. Department of Rheumatology, Tonan Hospital, Sapporo, Japan.
  12. Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  13. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

CER12680
2020 Vol.38, N°5 ,Suppl.127
PI 0011, PF 0016
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 32083551 [PubMed]

Received: 15/08/2019
Accepted : 18/12/2019
In Press: 19/02/2020
Published: 10/12/2020

Abstract

OBJECTIVES:
To clarify the efficacy and safety of calcineurin inhibitors (CNI) for treating adult-onset Still’s disease (AOSD).
METHODS:
This multicentre historical cohort study enrolled the consecutive patients with AOSD according to Yamaguchi classification criteria. The endpoints were set as the time from the initiation of treatment to events, the persistency rate of CNI and safety. Based on the recurrent event data analysis, these endpoints were evaluated for each event. We divided the events into two groups according to the treatment that included CNI or conventional therapy without CNI.
RESULTS:
One hundred seventy-eight patients with 247 events were analysed. CNI were predominantly used in 72 events with a recurrent history, typical skin rash, high ferritin levels, and/or severe complications such as macrophage activation syndrome, disseminated intravascular coagulation, serositis, meningitis. CNI led to a significantly longer event-free survival (hazard ratio: 0.57, 95% confidential interval: 0.32-0.99) after adjustment of concomitant medications. Subgroup analysis showed that CNI were effective for AOSD patients with high ALT level (hazard ratio: 0.11, 95% confidential interval: 0.02-0.59) and severe complications (hazard ratio: 0.11, 95% confidential interval: 0.01-0.94). The persistency rate of CNI was 71% at 5th year. Adverse events occurred more frequently in the CNI group (18% versus 8%, p=0.02); however, CNI did not involve in increased risk of adverse events, including nephrotoxicity, after adjustment (p=0.23).
CONCLUSIONS:
Our retrospective analysis suggested that CNI could be an effective and safe option for treating AOSD.

Rheumatology Article